Rabbit Recombinant Monoclonal MT4-MMP antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human, Mouse samples. Cited in 18 publications.
View Alternative Names
MT4MMP, MMP17, Matrix metalloproteinase-17, MMP-17, Membrane-type matrix metalloproteinase 4, Membrane-type-4 matrix metalloproteinase, MT-MMP 4, MTMMP4, MT4-MMP
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-MT4-MMP antibody [EP1270Y] (AB51075)
Immunofluorescent staining of HeLa cells using ab51075 (1 : 50).
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MT4-MMP antibody [EP1270Y] (AB51075)
ab51075 (1 : 50) staining human MT4-MMP in human lymphoma tissue by immunohistochemistry using paraffin embedded tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- WB
Unknown
Western blot - Anti-MT4-MMP antibody [EP1270Y] (AB51075)
All lanes:
Western blot - Anti-MT4-MMP antibody [EP1270Y] (ab51075) at 1/1000 dilution
All lanes:
Mouse brain tissue lysate at 10 µg
Secondary
All lanes:
Goat anti-Rabbit HRP labeled at 1/2000 dilution
Predicted band size: 67 kDa
Observed band size: 58 kDa
false
- IHC
CiteAb
Immunohistochemistry - Anti-MT4-MMP antibody [EP1270Y] (AB51075)
Immunohistochemistry-immunofluorescence using Anti-MT4-MMP antibody [EP1270Y], ab51075. Publication image from Andrés, V. et al., 2018, Nat Commun, 29500407. Legend direct from paper.
EnhancedαM integrin-dependent crawling of MT4-MMP-null patrolling monocytes on CCL2-inflamed endothelium. a Representative intravital microscopy images of CD115+/Ly6C– patrolling monocytes (CD115 in red and Ly6C in green) crawling on the CCL2-inflamed endothelium in the cremaster muscle of wild-type (MT4+/+) and MT4-MMP-null (MT4–/–) mice; the recording was performed in the presence of anti-Itgam blocking antibody (M1/70) or IgG isotype control. Arrowheads, arrows, and dots respectively indicate individual patrolling monocytes, blood flow, and monocyte trajectory. Time of recording is indicated. b The graph shows the numbers of crawling patrolling monocytes recorded in a in every venule from five independent mice per genotype and condition in two independent experiments. c Quantification of CD115+Ly6G- rolling (left) and adherent (right) monocytes in the CCL2-inflamed endothelium in the cremaster muscle of wild-type (MT4+/+) and MT4-MMP-null (MT4–/–) mice. n = 8 mice per genotype in two independent experiments. Data were tested by one-way ANOVA followed by Bonferroni’s post test in b and by two-tailed Student’s t-test in c. Results are expressed as mean ± SEM.*p < 0.05, **p < 0.01, and ***p < 0.001
- IHC
CiteAb
Immunohistochemistry - Anti-MT4-MMP antibody [EP1270Y] (AB51075)
Immunohistochemistry-immunofluorescence using Anti-MT4-MMP antibody [EP1270Y], ab51075. Publication image from Andrés, V. et al., 2018, Nat Commun, 29500407. Legend direct from paper.
Lack of MT4-MMP in BM-derived cells results in increased macrophage burden in atherosclerotic plaques and accelerated AT. a Representative images of Mac3 immunostaining (red; nuclei in blue) in transverse sections of aortas from Ldlr–/– mice transplanted with MT4-MMP+/+ (MT4+/+) or MT4-MMP–/– (MT4–/–) BM cells and fed a HFD for 8 weeks; scale bar, 20 µm. The right panel shows Mac3-positive cells quantified by Image J. n = 6 mice per genotype in two independent experiments. b Representative images of en face Oil Red-stained aortas from BM-transplanted Ldlr–/– and fed a HFD for 8 or 12 weeks (left) and graph shows the area (%) of Oil Red-positive lesions in the aortic arch (right); n = 6 and n = 16 mice per genotype for 8 and 12 weeks in two and three independent experiments, respectively. c Representative images of transverse sections of aortic sinus stained with H&E of BM-transplanted Ldlr–/– mice; scale bar, 200 µm. d Stary scoring (I–VI) of aortic lesions of BM-transplanted Ldlr–/– mice, shown as a percentage of all mice for each condition after feeding a HFD for 8 or 12 weeks; n = 6 and n = 16 mice per genotype and time point in two and three independent experiments. e Bar graphs show the percentage of BM-transplanted Ldlr–/– mice for each range of % of necrotic area (left) and fibrotic cap thickness (right) after 12 weeks of HFD; n = 16 mice per genotype in three independent experiments. Data were tested by two-tailed Student’s t-test in a, by two-way ANOVA followed by Bonferroni’s post test in b, and by χ2-test for a trend in d, e. Results are expressed as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001
Related conjugates and formulations (1)
-
Anti-MT4-MMP antibody [EP1270Y] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
MT4-MMP functions in tissue remodeling and extracellular matrix degradation. It does not typically form a part of larger protein complexes but works independently or in association with other cell surface molecules. MT4-MMP breaks down specific substrates contributing to processes like development reproduction and repair mechanisms. Its activity regulates the availability of bioactive molecules and extracellular matrix components impacting cellular behavior and tissue structure.
Pathways
MT4-MMP is involved in pathways critical for cell migration and angiogenesis. It participates in the activation of growth factors and modulates signaling pathways such as those related to integrins and vascular endothelial growth factor (VEGF). MT4-MMP associates with proteins like TIMP-2 which modulates its activity providing a regulatory mechanism within these pathways. This balance between activation and inhibition affects physiological and pathological tissue remodeling.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (18)
Recent publications for all applications. Explore the full list and refine your search
Reports of biochemistry & molecular biology 13:329-340 PubMed40330566
2025
Applications
Unspecified application
Species
Unspecified reactive species
Current biology : CB 32:3460-3476.e6 PubMed35809567
2022
Applications
Unspecified application
Species
Unspecified reactive species
Folia histochemica et cytobiologica 59:22-29 PubMed33560516
2021
Applications
Unspecified application
Species
Unspecified reactive species
Biochemical and biophysical research communications 522:1009-1014 PubMed31813546
2019
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 21:508-516 PubMed31746394
2019
Applications
Unspecified application
Species
Unspecified reactive species
Molecular & cellular proteomics : MCP 17:1487-1501 PubMed29716987
2018
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 9:910 PubMed29500407
2018
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 12:e0184767 PubMed28926609
2017
Applications
Unspecified application
Species
Unspecified reactive species
Cellular physiology and biochemistry : internation 42:198-210 PubMed28531887
2017
Applications
Unspecified application
Species
Unspecified reactive species
British journal of cancer 116:742-751 PubMed28196064
2017
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com